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EDITORIAL COMMENT
Unexpected, Dismal Left
Ventricular Function After
Surgery for Mitral Regurgitation
There Is Just No Excuse for it Anymore*
Thomas Wisenbaugh, MD, FACC
Honolulu, Hawaii
The American College of Cardiology/American Heart As-
sociation (ACC/AHA) guidelines (1) concerning surgery
for non-ischemic, severe mitral regurgitation (MR) are
complex in that they address 11 distinct clinical categories of
patients. Among those categories of patients for whom
there is still conflicting evidence or divergence of opinion
about the benefit of surgery (class II indications) are those
without symptoms who have either mildly depressed ejec-
tion fractions (0.50 to 0.60) or have a normal ejection
fraction but an end-systolic diameter of 45 to 55 mm
(ACC/AHA category 7, class IIa). Another important
category for whom there remains some controversy is the
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asymptomatic patient with preserved left ventricular (LV)
function in whom mitral valve repair is highly likely (category
9, class IIb). Waiting too long to perform surgery, particu-
larly when repair is not feasible or fails such that replace-
ment is required, has too often in the past resulted in a very
dismal outcome. Any remaining uncertainty about the need
for corrective surgery in theses two groups, particularly those
in the category with end-systolic diameters of 45 to 55 mm,
a size considered by some to be dangerous, needs to be
resolved.
What would be required to move either of these two
categories from class IIa and IIb, respectively, to a class I
indication (treatment is useful)? The difficulty in sending
asymptomatic patients to surgery is that the operation
cannot make them feel better (assuming they were truly
asymptomatic before surgery, an assumption that patients
may later find was incorrect). For asymptomatic patients
with preserved LV function amenable to repair (ACC/
AHA category 9) for whom the long-term natural history
may be good (except for those with flail valves), the question
can be restated: “What are the chances for successful repair
with survivorship and avoidance of a prosthesis?” Let us
examine some recent, relevant, published results of mitral
repair (Table 1) (2–5).
In the series reported Braunberger et al. (2), the post-
repair survival rate was said to be similar to the survival rate
for a normal population with the same age (56  10 years,
48% 20-year survival). Others have reported normal life
span after mitral repair. In two of the studies cited in
Table 1, re-operation rates were similar to those patients
undergoing valve replacement as their initial procedure,
which testifies to the durability of repair for non-rheumatic
regurgitation in experienced hands. With early mortality
rates of 1.4% to 2.9%, a risk of needing early re-operation
and mitral valve replacement (MVR) of about 1% to 2%,
and long-term survival that approximates that of the general
population, we are approaching a class I indication to
recommend mitral surgery to patients with very severe
MR who appear amenable to repair even if they are
asymptomatic and have preserved LV function. A compel-
ling case has certainly been made for this approach when the
etiology involves a flail leaflet (6), though this was not
known at the time the guidelines (1) were published in
1998. Even when severe MR is not due to such extreme
pathology, the reassurance provided by the current article of
Matsumura et al. (5) in this issue of the Journal, that the LV
dimensions you see before will be even better—and not
unexpectedly and dismally worse—after repair, should make
us lean more to early surgery if we have access to a center of
excellence.
The current article by Matsumura et al. (5) also carries
a message with regard to the category of asymptomatic
patient with an LV end-systolic diameter between 45
and 55 mm whose MR may or may not be amenable to
repair (ACC/AHA category 7). This has clearly been a
dangerous category in previous, smaller studies of MVR,
even in the era of chordal preservation. A previously
suggested cut point has been confirmed in the current study
of mitral valve preservation: when end-systolic diameter
increased from 35 to 40 mm to 40 to 45 mm, the risk of
having a postoperative ejection fraction of 50% increased
from 5% to 22%. For an end-systolic diameter45 mm, the
risk increased to 30%. These risks are greater if valve
replacement is performed and the valve apparatus cannot be
preserved. Thus, an end-systolic diameter 40 mm is
clearly a danger zone, and in my opinion, asymptomatic
patients with MR should be operated with a mitral-sparing
operation, if at all possible, when they enter it (class I
indication).
The article under discussion also has an impact on
ACC/AHA categories not targeted above: patients in
ACC/AHA category 4 are symptomatic or asymptomatic
patients with moderate LV dysfunction, ejection fraction
0.30 to 0.50, and/or end-systolic dimension 50 to 55 mm.
Though most of us would agree that these patients should
not be denied surgery on the basis of LV dysfunction alone,
the results of valve replacement are so poor with this degree
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of end-systolic enlargement that I do not tell my frail and
elderly patients who are in this category that they have a
class I indication for valve replacement. However, if their
valves were amenable to repair, and I knew I could get them
to surgeons like Matsumura et al. (5), I might do so: a
number of their patients with this degree of end-systolic
enlargement before surgery had normal LV function after
repair.
Other virtues of the current study include the following:
1) the study of a pure population with a degenerative
etiology; 2) the absence of coronary artery disease and the
need for coronary artery bypass graft, which negatively
impacts the results of mitral surgery; 3) the use of complex,
modern surgical techniques, including expanded polytetra-
fluoroethylene sutures for anterior leaflet chordae; and 4)
echo follow-up with data including the LV parameters.
These echo findings were of particular interest to me. A
long-held notion is that correction of MR “afterloads” the
LV and thus causes ejection fraction to fall. The current
study convincingly shows that both the end-diastolic and
-systolic diameters decrease after repair of MR, which
implies the ventricle has actually been “unloaded” and not
“afterloaded.” What does afterload the LV is disruption of
chordal integrity by radical mitral valvectomy. This is
responsible for most cases of unexpected, dismal outcome
after mitral valve surgery. And there is just no excuse for it
anymore.
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Table 1. Results of Repair for MR*
Reference n
Degenerative
Etiology (%)
30-Day
Mortality
% Needing
Early MVR % Late MR
Braunberger et al. (2) 162 90% 1.9% 1.9% 15%
Kobayashi et al. (3) 74 88% 1.4% 1% 17%
Mohty et al. (4) 679 100%† n/a n/a 20% (7%)‡
Matsumura et al. (5) 201 100% 2.9% 4% 6%
*Percentages are given for those needing early mitral valve replacement (MVR) for severe mitral regurgitation (MR) and those needing late MVR or having severe MR at
follow-up. †28% had overt coronary disease. ‡10-year reoperation rate for 1990s series.
n/a  not available.
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